Therapeutic targeting of genomic instability in triple negative breast cancer

The U.S. Defense Health Agency awarded a $907,170 Project Grant to the Provincial Health Services Authority (operating as BC Cancer) in Canada. This grant, provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports research on therapeutic targeting of genomic instability in triple-negative breast cancer. The 3-year project, running from September 2023 to September 2026, aims to advance the understanding and treatment of this aggressive form of breast cancer.

As a prime grantee, BC Cancer will conduct comprehensive research on the mechanisms of genomic instability in triple-negative breast cancer, with the goal of developing innovative therapeutic approaches. Additionally, as a sub-awardee, BC Cancer is contributing its expertise in precision oncology, genomic analysis, and bioinformatics to collaborative research initiatives with U.S. institutions such as Washington University, Northwestern University, and The Children's Hospital of Philadelphia. These multi-site projects focus on areas like whole-genome sequencing, knowledgebase development, and the integration of clinical and genomic data for cancer precision medicine.